Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I–II Colon Cancer
- 554 Downloads
Perineural invasion (PNI) in colon cancer (CC) has been associated with poorer prognosis even in stage II disease (T3–4 N0 M0). The aim of this study is to analyze prognostic histopathologic factors in stage II colon cancer in patients treated with curative surgery as established in National Comprehensive Cancer Network guidelines.
From a prospective database of CC cases, 507 patients with stage I–II disease who had undergone curative resection from January 2000 and December 2012 were identified. Of these patients, 17 % received 5-flurouracil-based adjuvant chemotherapy. Together with demographic and anatomic variables, we also studied perineural and lymphovascular invasion, degree of differentiation, and their correlation with disease-free survival.
Perineural invasion was identified in 57 patients (11.2 %) and lymphovascular invasion (LVI) in 82 (16.2 %) of the 507 patients. Perineural invasion was associated with LVI, the depth of invasion of the wall of the colon, and location of the tumor. Overall and disease-free survival of the complete series at 5 and 10 years was 89.5, 85.2, 83.2 and 81.6 %, respectively. In the PNI positive patients, disease-free survival at 5 years was significantly lower than in those without PNI (73.5 vs 88.6 %; p = 0.02). Multivariate analysis showed the presence of PNI to be a significant independent prognostic factor for disease-free survival (p = 0.025). Adjuvant chemotherapy reversed the impact of PNI on 5- to 10-year disease-free survival.
PNI a major prognostic and predictive factor in stage II colon cancer, and our results support the use of adjuvant chemotherapy in patients with PNI.
KeywordsOverall Survival Colon Cancer Adjuvant Chemotherapy National Comprehensive Cancer Network National Comprehensive Cancer Network
All authors the have read and approved the manuscript and it is not under consideration for publication elsewhere. The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of the manuscript
- 1.GLOBOCAN cancer fact sheets: Colorectal cancers. http://globocan.iarc.fr/old/FactSheets/cancers/colorectal-new.asp. Accessed 5 Apr 2016.
- 6.Shah MA, Renfro LA, Allegra CJ, et al. Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: Analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database. J Clin Oncol. 2016;34:843–53.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Tournigand C, Andre T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J Clin Oncol. 2012;30:3353–60.CrossRefPubMedGoogle Scholar
- 12.NCCN clinical practice guidelines in oncology. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Updated 2016. Accessed 5 October 2016.
- 16.O’Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010;28:3937–44.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.American Society of Anesthesiologists. New classification of physical status. Anesthesiology. 1963;24:111.Google Scholar
- 27.Jass JR, O’Brien J, Riddell RH, Snover DC, Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of surgically resected specimens of colorectal carcinoma: association of directors of anatomic and surgical pathology. Am J Clin Pathol. 2008;129:13–23.CrossRefPubMedGoogle Scholar
- 28.American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York: Springer New York; 2006:294.Google Scholar
- 29.Hamilton S, Bosman F, Boffetta P, et al. Carcinoma of the colon and rectum. In: Bosman FT, Carneiro F, Hruban R, Theise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: International Agency for Research on Cancer; 2010:134–46.Google Scholar
- 38.Niedzwiecki D, Bertagnolli MM, Warren RS, et al. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol. 2011;29:3146–52.CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Yothers G, O’Connell MJ, Lee M, et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol. 2013;31:4512–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Poeschl EM, Pollheimer MJ, Kornprat P, et al. Perineural invasion: Correlation with aggressive phenotype and independent prognostic variable in both colon and rectum cancer. J Clin Oncol. 2010;28:358–60; author reply e361–2.Google Scholar